Coriolan Lebreton

10PUBLICATIONS
87CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 15, 2026
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial.

Guillaume Beinse, Valerie Taly, Alexandra Leary

|Jan 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Félix Blanc-Durand, Benoit You, Yahia Adnani

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Aug 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.

Florence Joly, Alexandra Leary, Isabelle Ray-Coquard

|May 11, 2025
PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.

Nicolas Rippstein, Christophe Zemmour, Manuel Rodrigues

|Dec 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

Florence Joly, Fernando Bazan, Delphine Garbay

Pageof 2

Frequent Collaborators

7 joint publications

Isabelle Ray-Coquard

5 joint publications

Jérôme Alexandre

5 joint publications

Manuel Rodrigues

5 joint publications

Florence Joly